ENTRY       D10775            Mixture   Drug
NAME        Vonoprazan, amoxicillin and clarithromycin;
            Vonosap (TN);
            Voquenza (TN)
COMPONENT   Vonoprazan fumarate [DR:D10466], (Amoxicillin hydrate [DR:D00229] | Amoxicillin [DR:D07452]), Clarithromycin [DR:D00276]
CLASS       Metabolizing enzyme substrate
             DG02919  CYP2B6 substrate
             DG01639  CYP2C19 substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG02852  CYP3A/CYP3A4 inhibitor
              DG01522  CYP3A4 inhibitor
            Transporter inhibitor
             DG01622  ABCB1 inhibitor
REMARK      Therapeutic category: 6199
            ATC code: A02BD14
            Product: D10775<JP>
EFFICACY    Antibacterial
  DISEASE   Helicobacter pylori infection [DS:H00320]
COMMENT     Vonoprazan is metabolized by CYP3A4 with some contribution from CYP2B6, CYP2C19 and CYP2D6.
            Clarithromycin is an inhibitor and a substrate of CYP3A4, and it is an inhibitor of P-gp.
METABOLISM  Enzyme: CYP3A4 [HSA:1576]; CYP2B6 [HSA:1555], CYP2C19 [HSA:1557], CYP2D6 [HSA:1565]
INTERACTION CYP inhibition: CYP3A4 [HSA:1576]
            Transporter inhibition: ABCB1 [HSA:5243]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A02 DRUGS FOR ACID RELATED DISORDERS
               A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
                A02BD Combinations for eradication of Helicobacter pylori
                 A02BD14 Vonoprazan, amoxicillin and clarithromycin
                  D10775  Vonoprazan, amoxicillin and clarithromycin &lt;JP&gt;
            USP drug classification [BR:br08302]
             Gastrointestinal Agents
              Gastrointestinal Agents, Other
               Amoxicillin / Clarithromycin/ Vonoprazan
                D10775  Vonoprazan, amoxicillin and clarithromycin
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              61  Antibiotics
               619  Miscellaneous
                6199  Miscellaneous
                 D10775  Vonoprazan, amoxicillin and clarithromycin
            Drug groups [BR:br08330]
             Metabolizing enzyme substrate
              DG02919  CYP2B6 substrate
               D10775  Vonoprazan, amoxicillin and clarithromycin
              DG01639  CYP2C19 substrate
               D10775  Vonoprazan, amoxicillin and clarithromycin
              DG01644  CYP2D6 substrate
               D10775  Vonoprazan, amoxicillin and clarithromycin
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10775  Vonoprazan, amoxicillin and clarithromycin
             Metabolizing enzyme inhibitor
              DG02852  CYP3A/CYP3A4 inhibitor
               DG01522  CYP3A4 inhibitor
                D10775  Vonoprazan, amoxicillin and clarithromycin
             Transporter inhibitor
              DG01622  ABCB1 inhibitor
               D10775  Vonoprazan, amoxicillin and clarithromycin
            Antimicrobials [BR:br08307]
             Antibacterials
              Cell wall biosynthesis inhibitor, beta-lactam
               Extended spectrum penicillin
                D10775  Vonoprazan, amoxicillin and clarithromycin &lt;JP&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10775
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10775
             Drug transporters
              D10775
DBLINKS     PubChem: 313046633
///
